Haemonetics Stock Climbs As Citi Hikes Price Target On CSL Upside

Haemonetics Corporation stocks have been trading up by 16.93 percent after upbeat earnings and guidance fueled investor optimism.

Live Update At 15:02:36 EDT: On Thursday, October 08, 2026 Haemonetics Corporation stock [NYSE: HAE] is trending up by 16.93%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Haemonetics Corporation, ticker HAE, is trading like a quiet grinder that just got a fresh catalyst. The daily chart shows HAE stuck around $104–$109 for weeks, then suddenly jumping to a $118.93 close on 2026/10/08. That’s a clean breakout from the recent range, with a high of $121 the same day.

Intraday action backs that up. HAE spiked hard at the open from $115 to $121, then spent the rest of the session consolidating between roughly $117.5 and $120 with tight 5‑minute candles. That kind of hold near the top of the day usually tells traders that dip buyers are in control, not flippers dumping into strength.

Fundamentally, Haemonetics posted $339.38M in quarterly revenue and $33.01M in net income, with a fat 59% gross margin. Profit margins at roughly 7% and an EBITDA margin of 11.6% show a solid but still scaling operation. The balance sheet carries meaningful debt — about $1.17B long term — but liquidity looks comfortable with a 3.1 current ratio and $223.38M in cash.

More Breaking News

• CDE Stock Holds Discount As Silver Volatility Stays Elevated
• SBFM Stock Attracts Traders As Antiviral And Generics Story Builds
• DNN Stock Drifts Lower As Uranium Trader Focus Tightens
• Haemonetics Stock Pops As Citi Hikes Price Target To $123

Valuation is rich. HAE trades at a price-to-earnings ratio near 50 and a price-to-sales of 3.48, so the market is clearly paying up for growth and stability. For active traders, that means sentiment and news — not just value screens — will drive the next leg.

Why Traders Are Watching HAE Momentum Build

The real spark for HAE right now is Wall Street’s tone shift. Citigroup upgraded Haemonetics from Neutral to Buy and lifted its price target to $123, well above the prior $92 target and above the current analyst average of $108.40. When a major bank moves a target that aggressively, traders listen.

Citi’s thesis is specific, not hand‑wavy. The firm points to a new non‑exclusive supply agreement with CSL and actually quantifies the earnings upside. According to Citi, every 10% share recapture tied to that CSL deal could add about $0.13 to HAE’s earnings per share. That kind of math gives momentum traders something concrete to anchor a thesis around.

The market reacted right away. Haemonetics shares popped roughly 2.4% after the upgrade, with the stock trading around $108 at the time and still showing implied upside to the $123 target. Volume came in below the daily average, which tells me this first move was more of a controlled repricing than a full‑blown momentum stampede. For day and swing traders, that often sets up a “second leg” opportunity if volume expands on the next catalyst.

Under the surface, Haemonetics is also pushing its product story. The company’s earlier acquisition of Vivasure triggered a $6.1M milestone payment to Orchestra BioMed, closing out $11M in total consideration and setting up potential earnouts of up to $10M. That milestone confirms progress on Vivasure’s PerQseal Elite bioabsorbable vessel closure system — exactly the kind of specialty device that can support HAE’s high gross margins.

The catch is execution risk and cash outflow. Those earnouts only kick in if Vivasure‑related revenues ramp. Traders watching HAE should track future comments on Vivasure closely, especially into the upcoming earnings call on 2026/11/05, when management will have to connect these strategic moves to real numbers.

Conclusion

For active traders, HAE now sits at the crossroads of strong price action and rising analyst conviction. Haemonetics just broke out above weeks of sideways trading, held its intraday gains, and is backed by a fresh Citi upgrade pushing the price target to $123. With the stock recently near $118–$119, the Street is still signaling more room above.

But Haemonetics is not a cheap name at a 50x P/E. The market is paying for execution on the CSL supply agreement, continued margin strength, and future upside from Vivasure and its PerQseal Elite technology. The $6.1M milestone payment and up to $10M in earnouts tie HAE’s cash outlays directly to future Vivasure‑related revenues — a classic “pay as it performs” structure that traders should monitor over coming quarters. As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.”, and that mindset applies here as traders map out scenarios around how and when these milestones may start to flow through the numbers.

The next hard catalyst is the Q2 FY2027 earnings release and call on 2026/11/05. That is when traders finally get to see whether the CSL agreement is starting to show up in the income statement and how Haemonetics frames the Vivasure ramp. Expect volatility around that date; upgrades plus high valuation often lead to sharp moves if numbers surprise either way.

As Tim Sykes likes to remind traders, “The market doesn’t care about your opinion, only about price action and catalysts.” Haemonetics now has both — a bullish Wall Street reset and clear upcoming events. For those studying HAE, the job is to track the chart, respect risk, and let the confirmed catalysts, not hope, drive any trading plan.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.